相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Long noncoding RNAs and exosomal lncRNAs: classification, and mechanisms in breast cancer metastasis and drug resistance
Hassan Yousefi et al.
ONCOGENE (2020)
Editorial of special issue on pharmacotherapeutics of digestive tumors
Liwu Fu
GASTROENTEROLOGY REPORT (2020)
Intratumoral heterogeneity of EGFR-activating mutations in advanced NSCLC patients at the single-cell level
Longhua Guo et al.
BMC CANCER (2019)
Afatinib helped overcome subsequent resistance to osimertinib in a patient with NSCLC having leptomeningeal metastasis baring acquired EGFR L718Q mutation: a case report
Jing Liu et al.
BMC CANCER (2019)
Re-administration of osimertinib in osimertinib-acquired resistant non-small-cell lung cancer
Eiki Ichihara et al.
LUNG CANCER (2019)
Third-generation epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer
Natalie M. Andrews Wright et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2019)
Cancer statistics, 2019
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2019)
Emerging insights of tumor heterogeneity and drug resistance mechanisms in lung cancer targeted therapy
Zuan-Fu Lim et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
Chemotherapeutic drugs stimulate the release and recycling of extracellular vesicles to assist cancer cells in developing an urgent chemoresistance
Xiaokun Wang et al.
MOLECULAR CANCER (2019)
Exosomal miR-196a derived from cancer-associated fibroblasts confers cisplatin resistance in head and neck cancer through targeting CDKN1B and ING5
Xing Qin et al.
GENOME BIOLOGY (2019)
Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy
Ferdinandos Skoulidis et al.
NATURE REVIEWS CANCER (2019)
Osimertinib resistance in non-small cell lung cancer: Mechanisms and therapeutic strategies
Zheng-Hai Tang et al.
CANCER LETTERS (2018)
Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer
Suresh S. Ramalingam et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Tyrosine kinase inhibitors enhanced the efficacy of conventional chemotherapeutic agent in multidrug resistant cancer cells
Shaocong Wu et al.
MOLECULAR CANCER (2018)
Tumor-derived exosomes antagonize innate antiviral immunity
Liang Gao et al.
NATURE IMMUNOLOGY (2018)
Osimertinib as First-Line Treatment in EGFR-Mutated Non-Small-Cell Lung Cancer
Sanjay Popat
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Annexin A1 regulates EGFR activity and alters EGFR-containing tumour-derived exosomes in head and neck cancers
N. Raulf et al.
EUROPEAN JOURNAL OF CANCER (2018)
Rab17 regulates apical delivery of hepatic transcytotic vesicles
Anneliese C. Striz et al.
MOLECULAR BIOLOGY OF THE CELL (2018)
Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response
Gang Chen et al.
NATURE (2018)
LBA51Analysis of resistance mechanisms to osimertinib in patients with EGFR T790M advanced NSCLC from the AURA3 study
V A Papadimitrakopoulou et al.
ANNALS OF ONCOLOGY (2018)
LBA50Mechanisms of acquired resistance to first-line osimertinib: Preliminary data from the phase III FLAURA study
S S Ramalingam et al.
ANNALS OF ONCOLOGY (2018)
Evolution from genetics to phenotype: reinterpretation of NSCLC plasticity, heterogeneity, and drug resistance
Yingjiao Xue et al.
PROTEIN & CELL (2017)
The role of exosomes and miRNAs in drug-resistance of cancer cells
Duc-Hiep Bach et al.
INTERNATIONAL JOURNAL OF CANCER (2017)
Lung cancer: current therapies and new targeted treatments
Fred R. Hirsch et al.
LANCET (2017)
Tumour exosomes from cells harbouring PTPRZ1-MET fusion contribute to a malignant phenotype and temozolomide chemoresistance in glioblastoma
A-L Zeng et al.
ONCOGENE (2017)
The percentage of Epidermal Growth Factor Receptor (EGFR)-mutated neoplastic cells correlates to response to tyrosine kinase inhibitors in lung adenocarcinoma
Dario de Biase et al.
PLOS ONE (2017)
A global view of regulatory networks in lung cancer: An approach to understand homogeneity and heterogeneity
Jiapei Lu et al.
SEMINARS IN CANCER BIOLOGY (2017)
Exosome-delivered EGFR regulates liver microenvironment to promote gastric cancer liver metastasis
Haiyang Zhang et al.
NATURE COMMUNICATIONS (2017)
Dual MET and ERBB inhibition overcomes intratumor plasticity in osimertinib-resistant-advanced non-small-cell lung cancer (NSCLC)
A. Martinez-Marti et al.
ANNALS OF ONCOLOGY (2017)
Adipose Tissue Macrophage-Derived Exosomal miRNAs Can Modulate In Vivo and In Vitro Insulin Sensitivity
Wei Ying et al.
CELL (2017)
Amplification of EGFR Wild-Type Alleles in Non-Small Cell Lung Cancer Cells Confers Acquired Resistance to Mutation-Selective EGFR Tyrosine Kinase Inhibitors
Shigenari Nukaga et al.
CANCER RESEARCH (2017)
Exosome-Transmitted lncARSR Promotes Sunitinib Resistance in Renal Cancer by Acting as a Competing Endogenous RNA
Le Qu et al.
CANCER CELL (2016)
Communication by Extracellular Vesicles: Where We Are and Where We Need to Go
Mercedes Tkach et al.
CELL (2016)
The biology and function of exosomes in cancer
Raghu Kalluri
JOURNAL OF CLINICAL INVESTIGATION (2016)
Exosomal transfer of stroma-derived miR21 confers paclitaxel resistance in ovarian cancer cells through targeting APAF1
Chi Lam Au Yeung et al.
NATURE COMMUNICATIONS (2016)
Treatment of EGFR-Mutant Lung Cancers After Progression in Patients Receiving First-Line EGFR Tyrosine Kinase Inhibitors A Review
Zofia Piotrowska et al.
JAMA ONCOLOGY (2016)
Exosome-Mediated Transfer of microRNAs Within the Tumor Microenvironment and Neuroblastoma Resistance to Chemotherapy
Kishore B. Challagundla et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
Rab17 inhibits the tumourigenic properties of hepatocellular carcinomas via the Erk pathway
Kejia Wang et al.
TUMOR BIOLOGY (2015)
Molecular heterogeneity assessment by next-generation sequencing and response to gefitinib of EGFR mutant advanced lung adenocarcinoma
Emilio Bria et al.
ONCOTARGET (2015)
Exosome-Mediated Transfer of microRNAs Within the Tumor Microenvironment and Neuroblastoma Resistance to Chemotherapy
Kishore B. Challagundla et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
Mechanisms of resistance to EGFR tyrosine kinase inhibitors
Lihua Huang et al.
ACTA PHARMACEUTICA SINICA B (2015)
Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers
Helena A. Yu et al.
CLINICAL CANCER RESEARCH (2013)
Relative Abundance of EGFR Mutations Predicts Benefit From Gefitinib Treatment for Advanced Non-Small-Cell Lung Cancer
Qing Zhou et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
EGFR genetic heterogeneity of nonsmall cell lung cancers contributing to acquired gefitinib resistance
Shi-Xu Jiang et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
Cai-Hong Yun et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies
Hongbin Ji et al.
CANCER CELL (2006)
分享论文
